Table 7.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Pancreas After Kidney (PAK) Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		59	54	67	113	130	157	221	303	307	377
Tx with Antirejection Treatments		25	24	25	38	41	44	58	65	45	43
Antibodies	Category Usage	84.0%	66.7%	64.0%	76.3%	61.0%	59.1%	74.1%	53.8%	60.0%	48.8%
	ALG	20.0%	20.8%	16.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	4.0%	4.2%	8.0%	13.2%	17.1%	9.1%	1.7%	1.5%	2.2%	0.0%
	OKT3	68.0%	54.2%	48.0%	68.4%	51.2%	47.7%	62.1%	35.4%	26.7%	25.6%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	2.3%	22.4%	21.5%	33.3%	30.2%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	2.3%	1.7%	1.5%	2.2%	2.3%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.6%	4.4%	0.0%
Corticosteroids	Category Usage	40.0%	41.7%	48.0%	65.8%	78.0%	70.5%	84.5%	87.7%	86.7%	90.7%
	Steroids	40.0%	41.7%	48.0%	65.8%	78.0%	70.5%	84.5%	87.7%	86.7%	90.7%
Antimetabolites	Category Usage	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.